News|Articles|October 24, 2023

In the Lab eNewsletter

  • Pharmaceutical Technology's In the Lab eNewsletter, November 2023
  • Volume 18
  • Issue 11

Bettersize Unveils New Capabilities at AAPS 2023 PharmSci 360

Author(s)Susan Haigney

Bettersize US showcases their BeNano Series, Bettersizer 2600, and BetterPyc 380 instruments at the AAPS 2023 PharmSci 360 event.

Bettersize US announced on Oct. 22, 2023 that it is showcasing three of its instruments—the BeNano Series, Bettersizer 2600, and BetterPyc 380—at the AAPS 2023 PharmSci 360 event. The company is also highlighting its FLOW MODE coupled with high-performance liquid chromatography (HPLC), “which enables high-resolution nanoparticle size testing tailored to the precise needs of pharmaceutical professionals,” according to the company.

The BeNano Series features nanoparticle size and zeta potential analysis by three light scattering techniques. The Bettersizer 2600 offers particle size analysis by laser diffraction, with wet/dry dispersions, and the BetterPyc 380 features powder analysis by gas displacement method.

Bettersize Instruments is a provider of analytical instruments for material characterization, comprehensive solutions, and exceptional customer service. In August 2023, the company opened a new facility in Costa Mesa, Calif. to support North American material scientists, researchers, and engineers.

Visit Bettersize at PharmSci 360 at booth number 2135.

Source: Bettersize


Related to this article

Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation. | Image Credit: ©HockleyMedia24/peopleimages.com -stock.adobe.com
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 2
Mitigating nitrosamine risk requires assessing each product individually, says Bram Baert, Global Head of Regulatory Affairs at Capsugel, and Sandrine Picco, Senior Analytical Specialist on Capsugel's Innovaform Accelerator Team, in this interview with PharmTech.
Trophy and confetti on light background, top view with space for text. Victory concept | Image Credit: ©New Africa -stock.adobe.com
The winners of the CPHI Pharma Awards 2026 include a neurodegeneration platform, a track-and-trace packaging innovation, a enzymatic mRNA manufacturing technology, and a cell-free enzymatic biomanufacturing platform.
CPHI Milan 2026: Nitrosamine Risk Mitigation, Part 1
Capsugel's Bram Baert and Sandrine Picco argue that chasing zero nitrite in pharmaceutical excipients is often impractical and costly. They recommend setting scientifically justified, risk-based limits and consistently staying below them.